- Home
- News
- Topics
- FDA Week
- Inside CMS
- Inside Drug Pricing
- Health Exchange Alert
- Inside TeleHealth
- About Us
HHS says that if the Substance Abuse and Mental Health Services Administration is unable to complete a rulemaking that allows providers in opioid treatment programs to continue to initiate buprenorphine following a telehealth visit before the May 11 end of the public health emergency, SAMHSA will enact interim measures to bridge any gap that may result after the PHE ends.
Inside Health Policy is a subscription-fee-based daily digital news service from Inside Washington Publishers.
Economical site license packages are available to fit any size organization, from a few people at one location to company-wide access. For more information on how you can get greater access to Inside Health Policy for your office, contact Online Customer Service at 703-416-8505 or healthpolicy@iwpnews.com.
© 2002-2025. Inside Washington Publishers | Contact Us